Selected article for: "breath shortness cough fever and critical severe disease"
Author: Zheng, Kai-Lian; Xu, Ying; Guo, Yu-Feng; Diao, Le; Kong, Xiang-Yu; Wan, Xiao-Jian; Zhao, Feng; Ning, Fang-Zheng; Wang, Li-Bing; Qiao, Fan; Zhao, Jiang-Man; Zhou, Jia-Huan; Zhong, Yue-Qian; Wu, Shou-Xin; Chen, Yi; Jin, Gang; Dong, Yu-Chao
Title: Efficacy and safety of tocilizumab in COVID-19 patients
  • Cord-id: bwhoeram
  • Document date: 2020_10_8
    • ID: bwhoeram
    Snippet: In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19). We enrolled 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with confirmed COVID-19 between January 2020 and February 2020. Ninety-two patients were treated with tocilizumab, and 89 patients were treated conventionally. We analyzed the clinical manifestations, changes in CT scan images, and laboratory tests before and after tocilizum
    Document: In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19). We enrolled 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with confirmed COVID-19 between January 2020 and February 2020. Ninety-two patients were treated with tocilizumab, and 89 patients were treated conventionally. We analyzed the clinical manifestations, changes in CT scan images, and laboratory tests before and after tocilizumab treatment, and compared these results with the conventionally treated group. A significant reduction in the level of C-reactive protein was observed 1 week after tocilizumab administration. In some cases this meant the end of the IL-6-related cytokine storm. In addition, tocilizumab relieved fever, cough, and shortness of breath with no reported adverse drug reactions. These findings suggest tocilizumab improves clinical outcomes and is effective for treatment of patients with critical or severe COVID-19. However, future clinical trials are needed to better understand the impact of tocilizumab interference with IL-6 and provide a therapeutic strategy for treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest ct and logistic regression: 1, 2, 3, 4, 5
    • abnormal chest ct and logistic regression analysis: 1
    • active tuberculosis and logistic regression: 1, 2, 3
    • acute inflammation and liver hepatocyte: 1
    • acute inflammation and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
    • acute inflammation and logistic regression analysis: 1, 2, 3, 4
    • acute inflammatory response and liver hepatocyte: 1
    • acute inflammatory response and logistic regression: 1, 2
    • acute inflammatory response and logistic regression analysis: 1
    • acute phase and liver hepatocyte: 1
    • acute phase and liver renal: 1, 2, 3
    • acute phase and liver renal function: 1
    • acute phase and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute phase protein and logistic regression: 1, 2
    • acute phase protein and logistic regression analysis: 1
    • administration interval and logistic regression: 1
    • administration interval and logistic regression analysis: 1
    • liver renal and logistic regression analysis: 1, 2